

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/903,188	07/11/2001	Edward M. De Robertis	510015-258	1059	
759	07,25,2005		•		
Attention : Cha		37	EXAMI	NER	
OPPENHEIMER WOLFF & DONNELLY 38th Floor			ROMEO, DAVID S		
2029 Century Park East Los Angeles, CA 90067-3024			APTIBIT		
Lus Aligeles, CA	1 90007-3024		ART UNIT	PAPER NUMBER	
			1647	0	
			DATE MAILED: 07/23/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

<u> </u>		Application No.	Applicant(s)
	-	09/903,188	DE ROBERTIS ET AL.
	Office Action Summary	Examiner	Art Unit
		David S Romeo	1647
	The MAILING DATE of this communication ap		
A SH	O r Reply Ortened Statutory Period for Repl	LY IS SET TO EXPIRE 1 MO	•
- Externance - If the - If NO - Failu - Any r	MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1. SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period re to reply within the set or extended period for reply will, by statut eply received by the Office later than three months after the mailing patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a reploy within the statutory minimum of thirty (will apply and will expire SIX (6) MONTHER, cause the application to become ARA	30) days will be considered timely. IS from the mailing date of this communication.
1)🖂	Responsive to communication(s) filed on 11	July 2001 .	
2a)□		his action is non-final.	
3) [] Dispositi	Since this application is in condition for allow closed in accordance with the practice under on of Claims	ance except for formal matte	ers, prosecution as to the merits is 11, 453 O.G. 213.
4)⊠	Claim(s) 6-8,11 and 12 is/are pending in the	application.	
4	4a) Of the above claim(s) is/are withdra	wn from consideration.	
5)	Claim(s) is/are allowed.		
6)□	Claim(s) is/are rejected.		
7)	Claim(s) is/are objected to.		
	Claim(s) <u>6-8,11 and 12</u> are subject to restriction Papers	on and/or election requiremen	nt.
9)□ T	The specification is objected to by the Examine	er.	
	he drawing(s) filed on is/are: a)□ acce		Evaminer
	Applicant may not request that any objection to th		
11) 🗌 T	he proposed drawing correction filed on	_ is: a)☐ approved b)☐ disa	
	If approved, corrected drawings are required in re	_	pp. or od by the Examiner.
12)□ T	he oath or declaration is objected to by the Ex		
Priority u	nder 35 U.S.C. §§ 119 and 120		
_	Acknowledgment is made of a claim for foreigr	n priority under 35 U.S.C. & 1	19(a)-(d) or (f)
_	☐ All b)☐ Some * c)☐ None of:	, promy and 0, 0, 0, 0, 0, 0, 1	15(4) (4) 67 (1).
	1. Certified copies of the priority document	s have been received	
2	2. Certified copies of the priority document		ication No
3	Copies of the certified copies of the prior		
* Se	application from the International Bu se the attached detailed Office action for a list	reau (PCT Rule 17.2(a)).	
14)□ Ac	knowledgment is made of a claim for domesti	c priority under 35 U.S.C. § 1	19(e) (to a provisional application).
a)	\square The translation of the foreign language procknowledgment is made of a claim for domesti	visional application has been	received.
ttachment(s		00	
) 🔲 Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Infor	mary (PTO-413) Paper No(s) mal Patent Application (PTO-152)
Patent and Trad O-326 (Rev.	** **	ion Summary	Part of Paper No. 09

Application/Control Number: 09/903,188

Art Unit: 1647

5

15

20

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 6-8, 12 drawn to a FRZB-1 polypeptide, classified in class 530, subclass350.
- II. Claim 11, to the extent that it is drawn to a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 4, classified in class 536, subclass 23.5.
- III. Claim 11, to the extent that it is drawn to a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 8, classified in class 536, subclass 23.5.
- IV. Claim 11, to the extent that it is drawn to a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 10, classified in class 536, subclass 23.5.

The inventions are distinct, each from the other because of the following reasons:

The polynucleotides of Inventions II-IV are related to the polypeptide of Invention I by virtue of encoding same. The polynucleotide has utility for the recombinant production of the polypeptide in a host cell. Although the polynucleotide and polypeptide are related since the polynucleotide encodes the specifically claimed polypeptide, they are distinct inventions because they are physically and functionally distinct chemical entities, and the polypeptide product can be made by another and materially different process, such as by synthetic polypeptide synthesis or purification form the natural source. Further, the polynucleotide may be used for processes other than the production of the polypeptide, such as a nucleic acid hybridization assay.

The following pairwise combinations of products are independent and distinct, wherein neither member of a pair is required for the production or use of the other, and wherein each of

Application/Control Number: 09/903,188

Art Unit: 1647

5

10

15

the pair can be manufactured independently of the other and used for independent and distinct

Page 3

purposes: II and each of III-IV; III and IV. Further, nucleotide sequences encoding different

proteins are structurally distinct chemical compounds and are unrelated to one another. These

sequences are thus deemed to normally constitute independent and distinct inventions within the

meaning of 35 U.S.C. 121. Absent evidence to the contrary, each such nucleotide sequence is

presumed to represent an independent and distinct invention, subject to a restriction requirement

pursuant to 35 U.S.C. 121 and 37 CFR 1.141.

Because these inventions are distinct for the reasons given above and have acquired a

separate status in the art as shown by their different classification, restriction for examination

purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and the searches

required are not coextensive, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and have acquired a

separate status in the art because of their recognized divergent subject matter, restriction for

examination purposes as indicated is proper.

Claim 12 is generic to a plurality of disclosed patentably distinct species comprising:

1. a polypeptide encoded by the nucleotide sequence of SEQ ID NO: 4 or

comprising the amino acid sequence of SEQ ID NO: 3;

2. a polypeptide encoded by the nucleotide sequence of SEQ ID NO: 8 or

comprising the amino acid sequence of SEQ ID NO: 7; and

20

Application/Control Number: 09/903,188

Art Unit: 1647

Page 4

3. a polypeptide encoded by the nucleotide sequence of SEQ ID NO: 10 or comprising the amino acid sequence of SEQ ID NO: 9.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

5

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

10

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

15

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

20

25

ANY INQUIRY CONCERNING THIS COMMUNICATION OR EARLIER COMMUNICATIONS FROM THE EXAMINER SHOULD BE DIRECTED TO DAVID S. ROMEO WHOSE TELEPHONE NUMBER IS (703) 305-4050. THE EXAMINER CAN NORMALLY BE REACHED ON MONDAY THROUGH FRIDAY FROM 7:30 A.M. TO 4:00 P.M.

IF ATTEMPTS TO REACH THE EXAMINER BY TELEPHONE ARE UNSUCCESSFUL, THE EXAMINER'S SUPERVISOR, GARY KUNZ, CAN BE REACHED ON (703) 308-4623.

Application/Control Number: 09/903,188 Page 5 Art Unit: 1647 IF SUBMITTING OFFICIAL CORRESPONDENCE BY FAX, APPLICANTS ARE ENCOURAGED TO SUBMIT OFFICIAL CORRESPONDENCE TO THE FOLLOWING TC 1600 BEFORE AND AFTER FINAL RIGHTFAX NUMBERS: BEFORE FINAL (703) 872-9306 AFTER FINAL (703) 872-9307 IN ADDITION TO THE OFFICIAL RIGHTFAX NUMBERS ABOVE, THE TC 1600 FAX CENTER HAS THE FOLLOWING OFFICIAL FAX NUMBERS: (703) 305-3592, (703) 308-4242 AND (703) 305-3014. CUSTOMERS ARE ALSO ADVISED TO USE CERTIFICATE OF FACSIMILE PROCEDURES WHEN SUBMITTING A REPLY TO A NON-FINAL OR FINAL OFFICE ACTION BY FACSIMILE (SEE 37 CFR 1.6 AND 1.8). FAXED DRAFT OR INFORMAL COMMUNICATIONS SHOULD BE DIRECTED TO THE EXAMINER AT (703) 308-0294. ANY INQUIRY OF A GENERAL NATURE OR RELATING TO THE STATUS OF THIS APPLICATION OR PROCEEDING SHOULD BE DIRECTED TO THE GROUP RECEPTIONIST WHOSE TELEPHONE NUMBER IS (703) 308-0196.

15

10

5

DAVID ROMEO
PRIMARY EXAMINER
ART UNIT 1647

20 DSR JULY 22, 2003